Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02761694
Title ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors ArQule

Advanced Solid Tumor

Her2-receptor negative breast cancer

triple-receptor negative breast cancer


ARQ 751 + Paclitaxel

ARQ 751

ARQ 751 + Fulvestrant

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169 United States Details
Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Charleston Hematology Oncology Charleston South Carolina 29414 United States Details
The Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Research Dallas Texas 75230 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field